Carl G. Maki

Rush University Medical Center — United States

Medicine · Health Sciences

30h-index9.6kcitations112works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(72), Ubiquitin and proteasome pathways(24), Microtubule and mitosis dynamics(22), Cancer Research and Treatments(22), Epigenetics and DNA Methylation(20)

Publications110 total

ISG20L2 as a driver in the proliferation and invasion of lung adenocarcinoma via NKX2-1 regulation
Translational Cancer Research·2025Open Access
Supplementary Data from Coinhibition of Aurora Kinase B and SUV4-20H Induces Synthetic Lethality in Wild-type p53-Deficient Cancer Cells
2025Open Access
Figure S1 from Coinhibition of Aurora Kinase B and SUV4-20H Induces Synthetic Lethality in Wild-type p53-Deficient Cancer Cells
2025Open Access
Data from Coinhibition of Aurora Kinase B and SUV4-20H Induces Synthetic Lethality in Wild-type p53-Deficient Cancer Cells
2025Open Access
Figure S7 from Coinhibition of Aurora Kinase B and SUV4-20H Induces Synthetic Lethality in Wild-type p53-Deficient Cancer Cells
2025Open Access
Figure S6 from Coinhibition of Aurora Kinase B and SUV4-20H Induces Synthetic Lethality in Wild-type p53-Deficient Cancer Cells
2025Open Access
Figure S3 from Coinhibition of Aurora Kinase B and SUV4-20H Induces Synthetic Lethality in Wild-type p53-Deficient Cancer Cells
2025Open Access
Supplementary Movie #2 from Coinhibition of Aurora Kinase B and SUV4-20H Induces Synthetic Lethality in Wild-type p53-Deficient Cancer Cells
2025Open Access
Figure S2 from Coinhibition of Aurora Kinase B and SUV4-20H Induces Synthetic Lethality in Wild-type p53-Deficient Cancer Cells
2025Open Access
Figure S4 from Coinhibition of Aurora Kinase B and SUV4-20H Induces Synthetic Lethality in Wild-type p53-Deficient Cancer Cells
2025Open Access
Figure S8 from Coinhibition of Aurora Kinase B and SUV4-20H Induces Synthetic Lethality in Wild-type p53-Deficient Cancer Cells
2025Open Access
Supplementary Table 1 from Coinhibition of Aurora Kinase B and SUV4-20H Induces Synthetic Lethality in Wild-type p53-Deficient Cancer Cells
2025Open Access
Figure S10 from Coinhibition of Aurora Kinase B and SUV4-20H Induces Synthetic Lethality in Wild-type p53-Deficient Cancer Cells
2025Open Access
Figure S5 from Coinhibition of Aurora Kinase B and SUV4-20H Induces Synthetic Lethality in Wild-type p53-Deficient Cancer Cells
2025Open Access
Supplementary Movie #1 from Coinhibition of Aurora Kinase B and SUV4-20H Induces Synthetic Lethality in Wild-type p53-Deficient Cancer Cells
2025Open Access
Figure S9 from Coinhibition of Aurora Kinase B and SUV4-20H Induces Synthetic Lethality in Wild-type p53-Deficient Cancer Cells
2025Open Access
Coinhibition of Aurora Kinase B and SUV4-20H Induces Synthetic Lethality in Wild-type p53-Deficient Cancer Cells
Molecular Cancer Therapeutics·2025· 3 cited
Creb1 Promotes Dormancy Exit and is a Target to Overcome Endocrine Therapy Resistance in ER+ Breast Cancer Cells
SSRN Electronic Journal·2025Open Access
Potential biomarkers for MCL1 inhibitor sensitivity
Cell Signaling·2024Open Access
Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells
Journal of Biological Chemistry·2024· 5 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Lei Duan(16), Ricardo E. Perez(13), Hong Shen(8), Rory Geyer(6), Zhong Yu(5), Batzaya Davaadelger(5), Linghu Nie(4), Diarmuid Moran(4), Tomomi Inoue(4), Sarah Calhoun(4), Hatsumi Nagasawa(3), John B. Little(3), Lothar A. Blatter(3), Liqing Wu(3), Steven Gitelis(3), Peter M. Howley(2), Moammir Hasan Aziz(2), Mark M. Sasaki(2), Hongyan Zhu(2), Jeremy Stuart(2)